Theranexus, a unique clinical stage pharmaceutical company, has developed a versatile proprietary technology leading to first in class products to address severe unmet medical needs in brain disorders.
Location: France, Auvergne-Rhône-Alpes, Lyon
Employees: 11-50
Founded date: 2013
Investors 3
Mentions in press and media 11
| Date | Title | Description |
| 03.02.2022 | THERANEXUS : and BBDF start recruitment for phase I/II trial in Batten disease patients | THERANEXUS AND BBDF START RECRUITMENT FOR PHASE I/II TRIAL IN BATTEN DISEASE PATIENTS Lyon, France - Austin, TX, USA - 3 February 2022 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pionee... |
| 13.01.2022 | Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2021 - IMPLEMENTATION OF A NEW EQUITY LINE | Lyon, 13 January 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells (the "Com... |
| 20.12.2021 | THERANEXUS : announces its financial calendar for 2022 | THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2022 Lyon, December 20, 2021 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the int... |
| 20.12.2021 | Theranexus : THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2022 | Lyon, December 20, 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today annou... |
| 19.10.2021 | Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2021 AND PRESENTS ITS PROGRESS REPORT | Lyon, 19 October 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announc... |
| 19.10.2021 | Theranexus : Publishes its cash position as of 30 September 2021 and presents its progress report | THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2021 AND PRESENTS ITS PROGRESS REPORT Lyon, 19 October 2021 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the developm... |
| 30.09.2021 | Theranexus : Announces its first half 2021 results | THERANEXUS ANNOUNCES ITS FIRST HALF 2021 RESULTS Lyon, 30 September 2021 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interac... |
| 08.07.2021 | Theranexus : 2020 full-year results and update on the progress of main programs | THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 JUNE 2021 AND PRESENTS AN UPDATE ON THE PROGRESS OF ITS MAIN PROGRAMS Lyon, 8 July 2021 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pione... |
| 07.04.2021 | THERANEXUS Theranexus : 2020 full-year results and update on the progress of main programs | 2020 FULL-YEAR RESULTS AND UPDATE ON THE PROGRESS OF MAIN PROGRAMS Lyon, 7 April 2021 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulatin... |
| - | Theranexus reaches its primary endpoint in the proof of concept trial of THN102 in Excessive Daytime Sleepiness (EDS) | A major result for the company that validates for the first time in man its approach of combining a CNS drug with a glial connexin modulator. Theranexus, a clinical-stage biopharmaceutical company, announced today top-line results from its... |
Show more